<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020769</url>
  </required_header>
  <id_info>
    <org_study_id>SI-B001_208</org_study_id>
    <nct_id>NCT05020769</nct_id>
  </id_info>
  <brief_title>A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Baili Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Baili Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main purpose:&#xD;
&#xD;
        1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single&#xD;
           low dose combined with Osimertinib in patients with locally advanced or metastatic&#xD;
           NSCLC.&#xD;
&#xD;
        2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or&#xD;
           metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and&#xD;
           single-dose low-dose combination chemotherapy, and to select the optimal dose (combined&#xD;
           with RP2D) and mode of SI-B001 combined with Osimertinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>2 weeks</time_frame>
    <description>he DLT incident has not occurred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Progression-free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>SI-B001 combined with osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SI-B001 is administered by intravenous drip once weekly (QW). 120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI-B001</intervention_name>
    <description>Administration by intravenous infusion</description>
    <arm_group_label>SI-B001 combined with osimertinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female;&#xD;
&#xD;
          2. Age: ≥ 18 years;&#xD;
&#xD;
          3. Expected survival time ≥ 3 months;&#xD;
&#xD;
          4. Histopathologically and/or cytologically confirmed T790M-negative locally advanced or&#xD;
             metastatic lung cancer patients who are resistant after the first/second line of&#xD;
             third-generation EGFRTKI or resistant after the first/second line of TKI;&#xD;
&#xD;
          5. Agree to provide archival tumor tissue samples or fresh tissue samples of the primary&#xD;
             tumor or metastases within 6 months; if the subject cannot provide tumor tissue&#xD;
             samples, they can be evaluated by the investigator if they meet other inclusion and&#xD;
             exclusion criteria;&#xD;
&#xD;
          6. Must have at least one measurable lesion as defined by RECISTv1.1;&#xD;
&#xD;
          7. Performance status score ECOG0 or 1;&#xD;
&#xD;
          8. Toxicities from prior anticancer therapy have recovered to grade ≤ 2 as defined by&#xD;
             NCI-CTCAEv5.0 (except alopecia);&#xD;
&#xD;
          9. No severe cardiac dysfunction, left ventricular score ≥ 50%;&#xD;
&#xD;
         10. The level of organ function must meet the following criteria:&#xD;
&#xD;
               1. Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet&#xD;
                  count ≥ 80 × 109/L, hemoglobin ≥ 90 g/L;&#xD;
&#xD;
               2. Liver function: TBIL ≤ 1.5ULN (total bilirubin ≤ 3ULN for subjects with Gilbert's&#xD;
                  syndrome, liver cancer or liver metastases); AST and ALT ≤ 2.5ULN for subjects&#xD;
                  without liver metastases; AST and ALT ≤ 5.0ULN for subjects with liver&#xD;
                  metastases;&#xD;
&#xD;
               3. Renal function: creatinine (Cr) ≤ 1.5ULN, or creatinine clearance (Ccr) ≥ 50&#xD;
                  mL/min (according to CockcroftandGault formula).&#xD;
&#xD;
         11. Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, and activated&#xD;
             partial thromboplastin time (APTT) ≤ 1.5ULN;&#xD;
&#xD;
         12. Urine protein ≤ 2 + (measured by dipstick) or &lt; 1000 mg/24 h (urine);&#xD;
&#xD;
         13. Premenopausal women of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test 7 before starting treatment and must be non-lactating; all patients&#xD;
             (male or female) should take adequate barrier contraception measures throughout the&#xD;
             treatment cycle and 6 months after the end of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with MET, ALK, RET, HER2 mutations suggested by gene sequencing;&#xD;
&#xD;
          2. Patients who have previously received systemic chemotherapy in the first/second line&#xD;
             of systemic therapy;&#xD;
&#xD;
          3. Use chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major&#xD;
             surgery before the first dose;&#xD;
&#xD;
          4. History of significant cardiac disease, such as: symptomatic congestive heart failure&#xD;
             (CHF) ≥ grade 2 (CTCAE 5.0) history, New York Heart Association (NYHA) ≥ grade 2 heart&#xD;
             failure, acute coronary syndrome, etc.; QT prolongation (QTc &gt; 450 msec in men or QTc&#xD;
             &gt; 470 msec in women), complete left bundle branch block, third degree atrioventricular&#xD;
             block;&#xD;
&#xD;
          5. Active autoimmune diseases and inflammatory diseases, such as systemic lupus&#xD;
             erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis,&#xD;
             inflammatory bowel disease and Hashimoto's thyroiditis, except for type I diabetes,&#xD;
             hypothyroidism controllable by replacement therapy only, skin diseases not requiring&#xD;
             systemic treatment (such as vitiligo, psoriasis);&#xD;
&#xD;
          6. Other malignancies diagnosed within 5 years prior to first dose, Exceptions include:&#xD;
             radical basal cell carcinoma of the skin, scaly cell carcinoma of the skin, and/or&#xD;
             radical resection of carcinoma in situ;&#xD;
&#xD;
          7. Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure&#xD;
             &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg);&#xD;
&#xD;
          8. Pulmonary disease defined as ≥ grade 3 according to CTCAEv5.0, including resting&#xD;
             dyspnea, or requiring continuous oxygen therapy, or patients with a history of&#xD;
             interstitial lung disease (ILD);&#xD;
&#xD;
          9. Symptoms of active central nervous system metastases.However, patients with stable&#xD;
             parenchymal metastases can be stable, and whether it is stable or not is judged by the&#xD;
             investigator;&#xD;
&#xD;
         10. Patients with a history of hypersensitivity to recombinant humanized antibodies or&#xD;
             human-mouse chimeric antibodies or hypersensitivity to SI-B001 or any of the excipient&#xD;
             components of Osimertinib;&#xD;
&#xD;
         11. History of autologous or allogeneic stem cell transplantation;&#xD;
&#xD;
         12. In previous anthracycline (neo) adjuvant therapy, the cumulative dose of anthracycline&#xD;
             was &gt; 360 mg/m2;&#xD;
&#xD;
         13. Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active&#xD;
             hepatitis B virus infection (HBV-DNA copy number &gt; 104) or hepatitis C virus (HCV)&#xD;
             infection;&#xD;
&#xD;
         14. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia,&#xD;
             sepsis, etc.;&#xD;
&#xD;
         15. Received other unmarketed clinical study drugs or treatments before participating in&#xD;
             the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University Cancer Center (SYSUCC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hai Zhu</last_name>
    <phone>+86-13980051002</phone>
    <email>zhuhai@baili-pharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sa Xiao, PhD</last_name>
    <phone>+86-15013238943</phone>
    <email>xiaosa@baili-pharm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center (SYSUCC)</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Zhang</last_name>
      <email>zhangli6@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

